Authors

Latest:

Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

Anna Budina-Kolomets, MD

Latest:

Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma Therapy

A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.

Anna C. Ferrari, MD

Latest:

Dr. Ferrari on LBH589 and Bicalutamide in CRPC

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Anna C. Pavlick, DO

Anna C. Pavlick, BSN, MSc, DO, MBA, is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian

Latest:

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

Anna C. Pavlick, DO, NYU Langone Hospitals

Anna F. Farago, MD, PhD

Latest:

Dr. Farago on Frontline Immunotherapy Versus Maintenance Immunotherapy in SCLC

Anna F. Farago, MD, PhD, medical oncologist at the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the use of frontline immunotherapy versus maintenance immunotherapy in patients with small cell lung cancer (SCLC).

Anna Farago, MD, PhD

Latest:

Dr. Farago on Opportunities to Investigate Biomarkers for Small Cell Lung Cancer

Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).

Anna Kaminsky, DO

Latest:

Palliative Care: Let’s Keep the Conversation Open

As the end of my hematology/oncology fellowship draws near, I am reminded every day that oncology is not about winning or losing.

Anna Maria Storniolo, MD

Latest:

The Goodwill of Strangers Helps Build a Unique Resource for Cancer Research

Thousands of women have made the selfless choice to literally donate a precious piece of themselves by giving a breast tissue sample to the Susan G. Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center, a unique resource for researchers worldwide.

Anna Vioral, MSN, MEd, RN, OCN

Latest:

Anna Vioral on Multidisciplinary Chemotherapy Safety Standards

Anna Vioral, RN, OCN, from West Penn Allegheny Health System, on Multidisciplinary Chemotherapy Safety Standards.

Anne Chiang, MD

Anne Chiang, MD, PhD, is an associate professor of medicine in the Section of Medical Oncology and the associate cancer center director of Clinical Initiatives at the Yale School of Medicine

Latest:

Emerging Therapies for SCLC

Panelists discuss novel and investigational therapies under study for small cell lung cancer, including immunotherapy combinations and targeted approaches.

Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Latest:

Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.

Anne Covey, MD

Latest:

Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC

Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).

Anne Favret, MD

Latest:

Dr. Favret on Extending Survival and Improving Outcomes in Breast Cancer

Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.

Anne Hubbard

Latest:

Why Radiation Oncology Needs an APM

Alternative payment models (APMs) are the future of Medicare payment.

Anne Julia Klompenhouwer, MD

Latest:

Dr. Klompenhouwer on the Resection of Larger Hepatocellular Adenomas

Anne Julia Klompenhouwer, MD, Department of Surgery at Erasmus Medical Center in Rotterdam, The Netherlands, discusses when it is justified to resect a larger hepatocellular adenoma for patients with hepatocellular carcinoma (HCC).

Anne Katz, RN, PhD

Latest:

Anne Katz Discusses Cancer and Sexuality

Anne Katz, from the University of Manitoba, Discusses Cancer and Sexuality

Anne Kirchhoff, PhD, MPH

Latest:

Supporting Adolescents and Young Adults With Cancer From Diagnosis Through Survivorship

Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.

Anne Marie McCarthy, MD

Latest:

Dr. Anne Marie McCarthy on Measuring Breast Density with Computer Algorithms

Anne Marie McCarthy, MD, research fellow, Massachusetts General Hospital, discusses using computer algorithms to measure breast density.

Anne McTiernan, MD, PhD

Latest:

Dr. McTiernan on Biomarkers in Breast Cancer

Anne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.